RecruitingNCT07144319

Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy


Sponsor

Photocure

Enrollment

500 participants

Start Date

Mar 25, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

Blue light cystoscopy (BLC) is a diagnostic procedure in bladder cancer where the inside of the bladder is observed with a camera to detect bladder lesions. Unlike regular white light cystoscopy, blue light cystoscopy makes use of a drug that induces fluorescence under blue light preferentially in neoplastic and malignant cells that helps visualize bladder lesions during the cystoscopic procedure. Blue light cystoscopy has shown to improve detection of bladder cancer. Cystoscopy, including blue light cystoscopy, is a procedure involving assessment of the visual appearance of the bladder surface, leading to decisions of taking biopsies, remove suspicious areas and assign treatment options. The assessment is subjective and has a large operator variability. These shortcomings show an opportunity for computer aided detection (CADe) medical device to add value to both clinicians and patients. The objective of this data collection study is to build a high-quality, diverse data set of video, image recordings and relevant clinical data from BLC procedures performed as part of routine clinical practice to train a computer-aided detection (CADe) algorithm for real- time lesion detection during cystoscopy. The data will be used to support the training, non-clinical technical development and testing of such AI algorithms for use during cystoscopy and to provide documentation needed for training of such algorithms and to assist in guiding future validation of such algorithms. Exploratory purposes of the study is to use data to explore future AI algorithms in bladder cancer, such as computer-aided diagnosis (CADx) AI algorithms, image enhancement and cystoscopy improvement algorithms, including bladder mapping, tumor visualization, cystoscopy documentation, and combination models of image and clinical data including risk assessment, clinical outcomes, and disease modeling


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Age 18 or older
  • Written informed consent, approved by relevant IRB/IEC, signed
  • Hexvix/Cysview has been prescribed in the usual manner in accordance with the terms of the marketing authorization (see Appendix B)
  • Physician has planned to do a blue light cystoscopy on the patient and to obtain biopsies, if clinically indicated, of suspicious lesions with video confirmation.
  • Patient has not previously taken part in this study

Exclusion Criteria1

  • None

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(4)

Moffitt Cancer Center

Tampa, Florida, United States

Regents of the University of Michigan

Ann Arbor, Michigan, United States

Rutgers Cancer Institute

New Brunswick, New Jersey, United States

Oslo University Hospital

Oslo, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07144319


Related Trials